Document Detail


Efficacy of azithromycin in preventing lethal graft-versus-host disease.
MedLine Citation:
PMID:  23379441     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acute graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation (BMT) is initiated by donor T lymphocytes that recognize histocompatibility antigens presented by recipient dendritic cells (DCs). Current approaches to reduce GVHD are focused on suppressing donor T lymphocyte responses to alloantigens. However, these strategies may be inadequate in the setting of allogeneic transplants (particularly histoincompatible transplants), may increase the risk of tumour relapse and are associated with high rates of opportunistic infections. We hypothesized that inhibition of recipient DCs might suppress GVHD. We recently demonstrated in vitro that azithromycin, a macrolide antibiotic, also acts as a nuclear factor (NF)-κB inhibitor of murine DCs and inhibits their maturation and functions, including allogeneic responses. We investigated whether azithromycin could prevent alloreactions in a murine histoincompatibility model. Oral administration of azithromycin to recipient mice for 5 days during major-histoincompatible BMT suppressed lethal GVHD significantly, whereas ex-vivo lymphocyte function was not affected by the drug. These data suggest that azithromycin has potential as a novel prophylactic drug for lethal GVHD.
Authors:
S Iwamoto; E Azuma; T Kumamoto; M Hirayama; T Yoshida; M Ito; K Amano; M Ido; Y Komada
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental immunology     Volume:  171     ISSN:  1365-2249     ISO Abbreviation:  Clin. Exp. Immunol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-05     Completed Date:  2013-04-02     Revised Date:  2014-03-06    
Medline Journal Info:
Nlm Unique ID:  0057202     Medline TA:  Clin Exp Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  338-45     Citation Subset:  IM    
Copyright Information:
© 2012 British Society for Immunology.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Bacterial Agents / pharmacology,  therapeutic use*
Azithromycin / pharmacology,  therapeutic use*
Dendritic Cells / drug effects,  immunology
Female
Graft vs Host Disease / prevention & control*
Interleukin-10 / biosynthesis
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
NF-kappa B / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/NF-kappa B; 130068-27-8/Interleukin-10; 83905-01-5/Azithromycin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic derm...
Next Document:  Macroparasites at peripheral sites of infection are major and dynamic modifiers of systemic antimicr...